$70.32
1.65% today
Nasdaq, Oct 24, 09:47 pm CET
ISIN
US4622221004
Symbol
IONS

Ionis Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
one day ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the company was named as a top employer to work for by Science magazine in its annual Top Employer survey of the biopharmaceutical and related industries. In its first year of eligibility for the award, Ionis was ranked second based on industry-leading innovation, strong alignment of company and employ...
Neutral
Business Wire
3 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., Ionis' chief executive officer, was awarded the 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (OTS), a nonprofit organization that fosters academia and industry-based research and development of oligonucleotide therapeutics. The OTS Lifetime A...
Neutral
The Motley Fool
4 days ago
On October 17, 2025, Capricorn Fund Managers Ltd disclosed a new stake in Ionis Pharmaceuticals, acquiring approximately 162,800 shares in a trade estimated at $10.65 million based on average quarterly pricing.
Neutral
Business Wire
8 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, October 29th at 11:30 a.m. Eastern Time to discuss its third quarter 2025 financial results and progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited...
Neutral
Investors Business Daily
16 days ago
Ionis Pharmaceuticals guided to north of $5 billion in peak sales. Early Wednesday, Ionis stock was approaching a six-year high.
Neutral
Seeking Alpha
17 days ago
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Shareholder/Analyst Call October 7, 2025 8:30 AM EDT Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Sotirios Tsimikas - Senior Vice President of Global Cardiovascular Development Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Kenneth Newman - Senior Vice President of ...
Neutral
Business Wire
17 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today is hosting its 2025 Innovation Day in New York City. Ionis leaders will highlight the company's recent and near-term independent launches, growing pipeline of wholly owned medicines, innovative technology and clear path to sustained positive cash flow. Additionally, a leading physician will discuss the current t...
Positive
Reuters
about one month ago
Ionis Pharmaceuticals said on Monday its experimental brain disorder drug met the main goal in an early-to-late-stage study.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today